Literature DB >> 16861353

The effect of fetal hemoglobin on the survival characteristics of sickle cells.

Robert S Franco1, Zahida Yasin, Mary B Palascak, Peter Ciraolo, Clinton H Joiner, Donald L Rucknagel.   

Abstract

The determinants of sickle red blood cell (RBC) life span have not been well-defined but may include both intrinsic factors (eg, the tendency to sickle) and extrinsic factors (eg, the capacity of the reticuloendothelial system to remove defective RBCs). Fetal hemoglobin (HbF) is heterogeneously distributed among sickle RBCs; F cells contain 20% to 25% HbF, whereas the remainder have no detectable HbF (non-F cells). Autologous sickle RBCs were labeled with biotin and reinfused to determine overall survival, non-F- and F-cell survival, and time-dependent changes in HbF content (%HbF) for the surviving F cells. A total of 10 patients were enrolled, including 2 who were studied before and after the percentage of F cells was increased by treatment with hydroxyurea. As expected, F cells survived longer in all subjects. Non-F-cell survival correlated inversely with the percentage of F cells, with the time for 30% cell survival ranging from 6 days in patients with more than 88% F cells to 16 days in patients with less than 16% F cells. As the biotin-labeled RBCs aged in the circulation, the HbF content of the surviving F-cell population increased by 0.28%/d +/- 0.21%/d, indicating that within the F-cell population those with higher HbF content survived longer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16861353      PMCID: PMC1895865          DOI: 10.1182/blood-2005-09-008318

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

1.  The survival characteristics of dense sickle cells.

Authors:  R S Franco; Z Yasin; J M Lohmann; M B Palascak; T A Nemeth; M Weiner; C H Joiner; D L Rucknagel
Journal:  Blood       Date:  2000-11-15       Impact factor: 22.113

Review 2.  Intravenous immunoglobulin and anti-D in idiopathic thrombocytopenic purpura (ITP): mechanisms of action.

Authors:  A H Lazarus; J Freedman; J W Semple
Journal:  Transfus Sci       Date:  1998-09

3.  Individual variation in the production and survival of F cells in sickle-cell disease.

Authors:  G J Dover; S H Boyer; S Charache; K Heintzelman
Journal:  N Engl J Med       Date:  1978-12-28       Impact factor: 91.245

Review 4.  Mechanism of action of IVIG and anti-D in ITP.

Authors:  Alan H Lazarus; Andrew R Crow
Journal:  Transfus Apher Sci       Date:  2003-06       Impact factor: 1.764

5.  The effect of fetal hemoglobin on the sickling dynamics of SS erythrocytes.

Authors:  L S Sewchand; C S Johnson; H J Meiselman
Journal:  Blood Cells       Date:  1983

6.  RES uptake of red blood cell stroma: time course of effects on phagocytic function and susceptibility to endotoxin shock.

Authors:  D J Loegering
Journal:  Circ Shock       Date:  1983

7.  Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation.

Authors:  Kenyatta Cosby; Kristine S Partovi; Jack H Crawford; Rakesh P Patel; Christopher D Reiter; Sabrina Martyr; Benjamin K Yang; Myron A Waclawiw; Gloria Zalos; Xiuli Xu; Kris T Huang; Howard Shields; Daniel B Kim-Shapiro; Alan N Schechter; Richard O Cannon; Mark T Gladwin
Journal:  Nat Med       Date:  2003-11-02       Impact factor: 53.440

8.  Divergent nitric oxide bioavailability in men and women with sickle cell disease.

Authors:  Mark T Gladwin; Alan N Schechter; Frederick P Ognibene; Wynona A Coles; Christopher D Reiter; William H Schenke; Gyorgy Csako; Myron A Waclawiw; Julio A Panza; Richard O Cannon
Journal:  Circulation       Date:  2003-01-21       Impact factor: 29.690

Review 9.  An emerging role for nitric oxide in sickle cell disease vascular homeostasis and therapy.

Authors:  Christopher D Reiter; Mark T Gladwin
Journal:  Curr Opin Hematol       Date:  2003-03       Impact factor: 3.284

10.  Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia?

Authors:  D R Powars; J N Weiss; L S Chan; W A Schroeder
Journal:  Blood       Date:  1984-04       Impact factor: 22.113

View more
  44 in total

Review 1.  Genetic modifiers of sickle cell disease.

Authors:  Martin H Steinberg; Paola Sebastiani
Journal:  Am J Hematol       Date:  2012-05-28       Impact factor: 10.047

2.  Association of G6PD with lower haemoglobin concentration but not increased haemolysis in patients with sickle cell anaemia.

Authors:  Mehdi Nouraie; Noel S Reading; Andrew Campbell; Caterina P Minniti; Sohail R Rana; Lori Luchtman-Jones; Gregory J Kato; Mark T Gladwin; Oswaldo L Castro; Josef T Prchal; Victor R Gordeuk
Journal:  Br J Haematol       Date:  2010-05-09       Impact factor: 6.998

3.  Measurement of red cell lifespan and aging.

Authors:  Robert S Franco
Journal:  Transfus Med Hemother       Date:  2012-08-27       Impact factor: 3.747

4.  Evaluation of safety and pharmacokinetics of sodium 2,2 dimethylbutyrate, a novel short chain fatty acid derivative, in a phase 1, double-blind, placebo-controlled, single-dose, and repeat-dose studies in healthy volunteers.

Authors:  Susan P Perrine; William A Wargin; Michael S Boosalis; Wayne J Wallis; Sally Case; Jeffrey R Keefer; Douglas V Faller; William C Welch; Ronald J Berenson
Journal:  J Clin Pharmacol       Date:  2011-03-21       Impact factor: 3.126

5.  Metformin induces FOXO3-dependent fetal hemoglobin production in human primary erythroid cells.

Authors:  Yankai Zhang; Alireza Paikari; Pavel Sumazin; Carly C Ginter Summarell; Jacy R Crosby; Eric Boerwinkle; Mitchell J Weiss; Vivien A Sheehan
Journal:  Blood       Date:  2018-06-08       Impact factor: 22.113

6.  Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells.

Authors:  Mark A DeWitt; Wendy Magis; Nicolas L Bray; Tianjiao Wang; Jennifer R Berman; Fabrizia Urbinati; Seok-Jin Heo; Therese Mitros; Denise P Muñoz; Dario Boffelli; Donald B Kohn; Mark C Walters; Dana Carroll; David I K Martin; Jacob E Corn
Journal:  Sci Transl Med       Date:  2016-10-12       Impact factor: 17.956

7.  Modeling of red blood cell life-spans in hematologically normal populations.

Authors:  Rocío Lledó-García; Robert M Kalicki; Dominik E Uehlinger; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-07-31       Impact factor: 2.745

8.  In vivo HSPC gene therapy with base editors allows for efficient reactivation of fetal γ-globin in β-YAC mice.

Authors:  Chang Li; Aphrodite Georgakopoulou; Arpit Mishra; Sucheol Gil; R David Hawkins; Evangelia Yannaki; André Lieber
Journal:  Blood Adv       Date:  2021-02-23

Review 9.  Measurement of posttransfusion red cell survival with the biotin label.

Authors:  Donald M Mock; John A Widness; Peter Veng-Pedersen; Ronald G Strauss; Jose A Cancelas; Robert M Cohen; Christopher J Lindsell; Robert S Franco
Journal:  Transfus Med Rev       Date:  2014-04-05

10.  Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1c.

Authors:  Robert M Cohen; Robert S Franco; Paramjit K Khera; Eric P Smith; Christopher J Lindsell; Peter J Ciraolo; Mary B Palascak; Clinton H Joiner
Journal:  Blood       Date:  2008-08-11       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.